Faculty of Life Sciences, The University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, UK.
Eur J Endocrinol. 2013 Jun 1;169(1):K1-7. doi: 10.1530/EJE-13-0094. Print 2013 Jul.
Loss-of-function calcium-sensing receptor (CAR) mutations cause elevated parathyroid hormone (PTH) secretion and hypercalcaemia. Although full Car deletion is possible in mice, most human CAR mutations result from a single amino acid substitution that maintains partial function. However, here, we report a case of neonatal severe hyperparathyroidism (NSHPT) in which the truncated CaR lacks any transmembrane domain (CaR(R392X)), in effect a full CAR 'knockout'.
The infant (daughter of distant cousins) presented with hypercalcaemia (5.5-6 mmol/l corrected calcium (2.15-2.65)) and elevated PTH concentrations (650-950 pmol/l (12-81)) together with skeletal demineralisation. NSHPT was confirmed by CAR gene sequencing (homozygous c.1174C-to-T mutation) requiring total parathyroidectomy during which only two glands were located and removed, resulting in normalisation of her serum PTH/calcium levels.
The R392X stop codon was inserted into human CAR and the resulting mutant (CaR(R392X)) expressed transiently in HEK-293 cells.
CaR(R392X) expressed as a 54 kDa dimeric glycoprotein that was undetectable in conditioned medium or in the patient's urine. The membrane localisation observed for wild-type CaR in parathyroid gland and transfected HEK-293 cells was absent from the proband's parathyroid gland and from CaR(R392X)-transfected cells. Expression of the mutant was localised to endoplasmic reticulum consistent with its lack of functional activity.
Intriguingly, the patient remained normocalcaemic throughout childhood (2.5 mM corrected calcium, 11 pg/ml PTH (10-71), age 8 years) but exhibited mild asymptomatic hypocalcaemia at age 10 years, now treated with 1-hydroxycholecalciferol and Ca2+ supplementation. Despite representing a virtual CAR knockout, the patient displays no obvious pathologies beyond her calcium homeostatic dysfunction.
钙敏感受体 (CaR) 失能突变导致甲状旁腺激素 (PTH) 分泌增加和高钙血症。虽然在小鼠中完全缺失 CaR 是可能的,但大多数人类 CaR 突变仅导致单个氨基酸取代,从而保持部分功能。然而,在这里,我们报告了一例新生儿严重甲状旁腺功能亢进症 (NSHPT) 病例,其中截短的 CaR 缺乏任何跨膜结构域 (CaR(R392X)),实际上是完整的 CaR“敲除”。
该婴儿(远房表亲的女儿)表现为高钙血症(5.5-6mmol/l 校正钙(2.15-2.65))和升高的 PTH 浓度(650-950pmol/l(12-81)),同时伴有骨骼脱矿化。通过 CaR 基因测序(纯合 c.1174C-to-T 突变)确认 NSHPT 需要进行甲状旁腺全切除术,在此期间仅发现并切除了两个腺体,导致血清 PTH/钙水平正常化。
将 R392X 终止密码子插入人 CaR 中,随后在 HEK-293 细胞中瞬时表达所得突变体(CaR(R392X))。
CaR(R392X) 表达为 54kDa 二聚糖蛋白,在条件培养基或患者尿液中均无法检测到。在甲状旁腺和转染的 HEK-293 细胞中观察到的野生型 CaR 的膜定位在该患者的甲状旁腺和 CaR(R392X)转染细胞中均不存在。突变体的表达定位于内质网,与其缺乏功能活性一致。
有趣的是,该患者在整个儿童期(校正钙 2.5mmol/l,PTH 11pg/ml(10-71),8 岁)保持正常钙血症,但在 10 岁时出现轻度无症状低钙血症,现接受 1-羟胆钙化醇和 Ca2+补充治疗。尽管代表了虚拟的 CaR 敲除,但该患者除钙稳态功能障碍外,没有明显的病理表现。